Syncom Formulations Limited is a leading Indian pharmaceutical company. The company manufactures and markets a wide range of pharmaceutical products, including anti-infectives, analgesics, anti-inflammatory drugs, and gastrointestinal drugs. Syncom Formulations has a strong track record of profitability and growth, and it is well-positioned to benefit from the growing demand for pharmaceutical products in India and around the world.
Syncom Formulations Share Price Target 2023
The average Syncom Formulations share price target for 2023 is between Rs 10 and Rs 12. This represents a potential upside of 10-20% from the current price.
Analysts are bullish on Syncom Formulations for the following reasons:
- The company has a strong track record of profitability and growth.
- Syncom Formulations is well-positioned to benefit from the growing demand for pharmaceutical products in India and around the world.
- The company is investing heavily in new products and markets.
- Syncom Formulations also has a strong management team with a proven track record of success.
Syncom Formulations Share Price Target 2024
The average Syncom Formulations share price target for 2024 is between Rs 12 and Rs 14. This represents a potential upside of 20-30% from the current price.
Analysts are bullish on Syncom Formulations for the same reasons listed above, as well as the following:
- The company is expected to benefit from the continued economic growth in India.
- Syncom Formulations is also expected to benefit from the government’s focus on healthcare.
- The company is also planning to expand its exports.
Syncom Formulations Share Price Target 2025
The average Syncom Formulations share price target for 2025 is between Rs 14 and Rs 16. This represents a potential upside of 30-40% from the current price.
Analysts are bullish on Syncom Formulations for the same reasons listed above, as well as the following:
- The company is expected to achieve significant growth in its anti-infectives, analgesics, anti-inflammatory drugs, and gastrointestinal drugs businesses.
- Syncom Formulations is also expected to benefit from the growing demand for specialized pharmaceutical products.
Syncom Formulations Share Price Target 2026-2030
Analysts are bullish on Syncom Formulations for the long term, with share price targets for 2026-2030 ranging from Rs 16 to Rs 20. This represents a potential upside of 50-100% from the current price.
Analysts are bullish on Syncom Formulations for the following reasons:
- The company is well-positioned to benefit from the growing demand for pharmaceutical products in India and around the world.
- Syncom Formulations is investing heavily in new products and markets.
- The company also has a strong management team with a proven track record of success.
Risks to Consider
While Syncom Formulations is a well-established company with a bright future, there are some risks to consider before investing in the stock. These risks include:
- The company’s profitability is dependent on the global economic conditions.
- Syncom Formulations is also exposed to the risk of currency fluctuations.
- The company is also exposed to the risk of competition from other pharmaceutical companies.
Conclusion
Overall, Syncom Formulations is a well-managed company with a strong track record of profitability and growth. The company is well-positioned to benefit from the growing demand for pharmaceutical products in India and around the world.
Analysts are bullish on Syncom Formulations for the long term, with share price targets for 2026-2030 ranging from Rs 16 to Rs 20. This represents a potential upside of 50-100% from the current price.
